Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Trial ID or NCT#

NCT06291376

Status

recruiting iconRECRUITING

Purpose

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Immunoglobulin A Nephropathy (IgAN)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Jackson Kim, MD
Jackson Kim, MD
Nephrologist
Clinical Assistant Professor, Medicine - Nephrology
Richard Lafayette
Richard Lafayette
Nephrologist
Professor of Medicine (Nephrology)

Contact us to find out if this trial is right for you.

Contact

Shiktj Dave
650-723-2240

SEND MESSAGE

View on ClinicalTrials.gov